NASDAQ:CAPR Capricor Therapeutics (CAPR) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free CAPR Stock Alerts $6.77 +0.46 (+7.29%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$6.19▼$7.0450-Day Range$3.61▼$6.8852-Week Range$2.68▼$8.22Volume382,685 shsAverage Volume412,169 shsMarket Capitalization$213.26 millionP/E RatioN/ADividend YieldN/APrice Target$24.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Capricor Therapeutics alerts: Email Address Capricor Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside254.5% Upside$24.00 Price TargetShort InterestBearish10.25% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.83) to $0.12 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.07 out of 5 starsMedical Sector759th out of 939 stocksPharmaceutical Preparations Industry354th out of 435 stocks 3.5 Analyst's Opinion Consensus RatingCapricor Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.00, Capricor Therapeutics has a forecasted upside of 254.5% from its current price of $6.77.Amount of Analyst CoverageCapricor Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.25% of the outstanding shares of Capricor Therapeutics have been sold short.Short Interest Ratio / Days to CoverCapricor Therapeutics has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.Change versus previous monthShort interest in Capricor Therapeutics has recently increased by 19.63%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCapricor Therapeutics does not currently pay a dividend.Dividend GrowthCapricor Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CAPR. Previous Next 2.5 News and Social Media Coverage News SentimentCapricor Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Capricor Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for CAPR on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows7 people have added Capricor Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Capricor Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.50% of the stock of Capricor Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 21.68% of the stock of Capricor Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Capricor Therapeutics are expected to grow in the coming year, from ($0.83) to $0.12 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Capricor Therapeutics is -7.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Capricor Therapeutics is -7.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCapricor Therapeutics has a P/B Ratio of 9.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Capricor Therapeutics Stock (NASDAQ:CAPR)Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. Read More CAPR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CAPR Stock News HeadlinesMarch 21, 2024 | globenewswire.comCapricor Therapeutics to Present at Upcoming Investor ConferencesMarch 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cyclo Therapeutics on Strong Clinical and Financial ProspectsMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 18, 2024 | americanbankingnews.comFY2024 Earnings Forecast for Capricor Therapeutics Inc (NASDAQ:CAPR) Issued By Cantor FitzgeraldMarch 14, 2024 | finance.yahoo.comEarnings Beat: Capricor Therapeutics, Inc. (NASDAQ:CAPR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMarch 12, 2024 | markets.businessinsider.comBuy Rating Affirmed: Lineage Therap’s Growth and Innovation Poised to Transform Biotech LandscapeMarch 6, 2024 | markets.businessinsider.comCapricor Therapeutics: Strong Buy Rating Backed by Robust Financials and Promising Clinical ProgressMarch 6, 2024 | globenewswire.comCapricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 3, 2024 | finance.yahoo.comCapricor Therapeutics Full Year 2023 Earnings: Beats ExpectationsMarch 3, 2024 | seekingalpha.comCapricor Therapeutics, Inc. (CAPR) Q4 2023 Earnings Call TranscriptMarch 2, 2024 | finance.yahoo.comCapricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | finance.yahoo.comQ4 2023 Capricor Therapeutics Inc Earnings CallFebruary 29, 2024 | benzinga.comRecap: Capricor Therapeutics Q4 EarningsFebruary 29, 2024 | finance.yahoo.comCapricor Therapeutics Inc (CAPR) Reports Encouraging Year-End Financials and Advances in DMD TherapyFebruary 29, 2024 | globenewswire.comCapricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateFebruary 28, 2024 | benzinga.comCapricor Therapeutics's Earnings OutlookFebruary 28, 2024 | markets.businessinsider.comCapricor Therapeutics is about to announce earnings — here's what Wall Street expectsFebruary 27, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Ultragenyx Pharmaceutical (RARE), Rocket Pharmaceuticals (RCKT)February 27, 2024 | markets.businessinsider.comCapricor Therapeutics Granted Type-B Meeting With FDA For CAP-1002 Muscular Dystrophy Drug, Stock UpFebruary 27, 2024 | marketwatch.comCapricor Therapeutics Shares Rise 8% After FDA Meeting SetFebruary 27, 2024 | globenewswire.comCapricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular DystrophyFebruary 22, 2024 | finance.yahoo.comCapricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29February 22, 2024 | globenewswire.comCapricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29February 20, 2024 | morningstar.comCapricor Therapeutics Inc CAPRFebruary 20, 2024 | msn.comCapricor scales up manufacturing capacity for DMD therapyFebruary 20, 2024 | finance.yahoo.comCapricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward CommercializationSee More Headlines Receive CAPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today3/27/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CAPR CUSIPN/A CIK1133869 Webwww.capricor.com Phone310-358-3200Fax415-875-7075EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$24.00 High Stock Price Target$40.00 Low Stock Price Target$8.00 Potential Upside/Downside+254.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,290,000.00 Net Margins-88.52% Pretax Margin-88.52% Return on Equity-299.67% Return on Assets-45.54% Debt Debt-to-Equity RatioN/A Current Ratio1.63 Quick Ratio1.63 Sales & Book Value Annual Sales$25.18 million Price / Sales8.47 Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book9.27Miscellaneous Outstanding Shares31,500,000Free Float27,565,000Market Cap$213.26 million OptionableOptionable Beta3.94 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesFrank I. Litvack M.D. (Age 59)Independent Executive Chairman of the Board Linda Marban Ph.D. (Age 51)President, Chief Executive Officer, Director Anthony Bergmann (Age 32)Chief Financial Officer, Principal Accounting Officer Karen G. Krasney J.D. (Age 62)Executive Vice President, General Counsel Thomas Lyle Copmann Ph.D. (Age 61)Vice President - Regulatory Affairs and Drug Development Houman Hemmati M.D.Ph.D., Vice President - Medical & Clinical Development, New TherapiesLuis Rodriguez-Borlado Ph.D.Vice President - Regenerative TherapiesRachel Smith Ph.D. (Age 36)Vice President - Research & Development Deborah Ascheim M.D.Chief Medical OfficerJoshua A. Kazam (Age 40)Director More ExecutivesKey CompetitorsInventivaNASDAQ:IVAAbeona TherapeuticsNASDAQ:ABEODesign TherapeuticsNASDAQ:DSGNIncannex HealthcareNASDAQ:IXHLAlimera SciencesNASDAQ:ALIMView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 13,086 shares on 3/11/2024Ownership: 3.785%Goldman Sachs Group Inc.Sold 9,309 shares on 3/1/2024Ownership: 0.049%GSA Capital Partners LLPSold 10,835 shares on 2/16/2024Ownership: 0.107%Vanguard Group Inc.Bought 13,086 shares on 2/15/2024Ownership: 3.785%Citadel Advisors LLCBought 3,000 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions CAPR Stock Analysis - Frequently Asked Questions Should I buy or sell Capricor Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CAPR shares. View CAPR analyst ratings or view top-rated stocks. What is Capricor Therapeutics' stock price target for 2024? 2 brokerages have issued 1 year price targets for Capricor Therapeutics' shares. Their CAPR share price targets range from $8.00 to $40.00. On average, they predict the company's share price to reach $24.00 in the next twelve months. This suggests a possible upside of 254.5% from the stock's current price. View analysts price targets for CAPR or view top-rated stocks among Wall Street analysts. How have CAPR shares performed in 2024? Capricor Therapeutics' stock was trading at $4.89 at the start of the year. Since then, CAPR shares have increased by 38.4% and is now trading at $6.77. View the best growth stocks for 2024 here. Are investors shorting Capricor Therapeutics? Capricor Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 3,230,000 shares, an increase of 19.6% from the February 29th total of 2,700,000 shares. Based on an average daily volume of 274,400 shares, the short-interest ratio is currently 11.8 days. View Capricor Therapeutics' Short Interest. When is Capricor Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CAPR earnings forecast. How were Capricor Therapeutics' earnings last quarter? Capricor Therapeutics Inc (NASDAQ:CAPR) issued its quarterly earnings results on Thursday, February, 29th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.21. The biotechnology company earned $12.09 million during the quarter, compared to analysts' expectations of $5.80 million. Capricor Therapeutics had a negative net margin of 88.52% and a negative trailing twelve-month return on equity of 299.67%. What other stocks do shareholders of Capricor Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Capricor Therapeutics investors own include Marinus Pharmaceuticals (MRNS), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Inovio Pharmaceuticals (INO), Trevena (TRVN), Dynavax Technologies (DVAX), Chesapeake Energy (CHKAQ), OPKO Health (OPK) and Advanced Micro Devices (AMD). Who are Capricor Therapeutics' major shareholders? Capricor Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.79%), Vanguard Group Inc. (3.78%), Northern Trust Corp (0.41%), Jump Financial LLC (0.17%), GSA Capital Partners LLP (0.11%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include David B Musket, Paul Gisbert Auwaerter and Xavier Avat. View institutional ownership trends. How do I buy shares of Capricor Therapeutics? Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CAPR) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe 3rd Revolution in WarfareWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsIs AI Energy Really 4 Million Times More Powerful Than Oil? (Surprising Answer)Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.